- Home
- XNCR
XNCR
Xencor Inc.
as 07-26-2024 4:00pm EST
Xencor Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on discovering and developing engineered monoclonal antibody and other protein therapeutics to treat severe and life-threatening diseases such with unmet medical needs. The company uses its XmAb technology platform to create antibody product candidates such as XmAb5871 and XmAb7195. It also has a few pre-clinical stage candidates in its portfolio such as XmAb14045, XmAb662 among others. It earns its revenue from research and development collaborations and licenses of its internally developed drug candidates.
Upcoming Earnings Alert:
Get ready for potential market movements as Xencor Inc. XNCR prepares to release earnings report on 01 Aug 2024.
| Founded: | 1997 | Country: | United States |
| Employees: | N/A | City: | PASADENA |
| Market Cap: | 1.5B | IPO Year: | 2013 |
| Target Price: | $35.63 | AVG Volume (30 days): | 444.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.19 | EPS Growth: | N/A |
| 52 Week Low/High: | $16.49 - $26.84 | Next Earning Date: | 08-01-2024 |
| Revenue: | $162,181,000 | Revenue Growth: | 65.41% |
| Revenue Growth (this year): | -48.98% | Revenue Growth (next year): | 65.13% |
Stock Insider Trading Activity of Xencor Inc. (XNCR)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Valente Nancy | XNCR | EVP, Chief Development Officer | May 2 '24 | Sell | $23.58 | 4,745 | $111,871.92 | 55,115 | SEC Form 4 |
| Eckert Celia | XNCR | SVP, GENERAL COUNSEL | Mar 11 '24 | Sell | $23.50 | 850 | $19,976.53 | 45,465 | SEC Form 4 |
| Dahiyat Bassil I | XNCR | PRESIDENT & CEO | Mar 11 '24 | Sell | $23.50 | 2,741 | $64,418.43 | 351,894 | SEC Form 4 |
| Desjarlais John R | XNCR | SR. VICE PRESIDENT & CSO | Mar 11 '24 | Sell | $23.50 | 1,280 | $30,082.30 | 186,433 | SEC Form 4 |
| Kuch John J | XNCR | SR. VICE PRESIDENT & CFO | Mar 11 '24 | Sell | $23.50 | 849 | $19,953.03 | 121,070 | SEC Form 4 |
| GUSTAFSON KURT A | XNCR | Director | Mar 6 '24 | Sell | $23.18 | 14,000 | $324,452.80 | 6,007 | SEC Form 4 |
| Kuch John J | XNCR | SR. VICE PRESIDENT & CFO | Mar 5 '24 | Sell | $23.43 | 4,474 | $104,821.35 | 121,919 | SEC Form 4 |
| Dahiyat Bassil I | XNCR | PRESIDENT & CEO | Mar 5 '24 | Sell | $23.43 | 12,528 | $293,518.51 | 300,097 | SEC Form 4 |
| Eckert Celia | XNCR | SVP, GENERAL COUNSEL | Mar 5 '24 | Sell | $23.43 | 3,892 | $91,185.67 | 33,226 | SEC Form 4 |
| Desjarlais John R | XNCR | SR. VICE PRESIDENT & CSO | Mar 5 '24 | Sell | $23.43 | 6,629 | $155,310.84 | 166,989 | SEC Form 4 |
| Desjarlais John R | XNCR | SR. VICE PRESIDENT & CSO | Feb 13 '24 | Sell | $19.38 | 54,108 | $1,048,742.90 | 161,675 | SEC Form 4 |
| GORMAN KEVIN CHARLES | XNCR | Director | Feb 13 '24 | Buy | $19.12 | 53 | $1,013.36 | 5,060 | SEC Form 4 |
| Dahiyat Bassil I | XNCR | PRESIDENT & CEO | Dec 29 '23 | Sell | $20.93 | 45,000 | $941,670.00 | 312,929 | SEC Form 4 |
Latest Xencor Inc. News
XNCR Breaking Stock News: Dive into XNCR Ticker-Specific Updates for Smart Investing
Argus Research
3 days ago
XNCR: What does Argus have to say about XNCR?
Argus Research
10 days ago
XNCR: Raising target price to $21.00
Argus Research
17 days ago
XNCR: What does Argus have to say about XNCR?
Simply Wall St.
a month ago
Xencor (NASDAQ:XNCR) shareholders have endured a 52% loss from investing in the stock five years ago
MT Newswires
a month ago
Raymond James Adjusts Price Target on Xencor to $40 From $58, Maintains Strong Buy Rating
MT Newswires
a month ago
BMO Capital Adjusts Xencor's Price Target to $32 From $34, Keeps Outperform Rating
MT Newswires
a month ago
RBC Trims Price Target on Xencor to $31 From $32, Maintains Outperform, Speculative Risk Rating
MT Newswires
a month ago
Wedbush Cuts Price Target on Xencor to $34 From $36, Maintains Outperform Rating
Compare XNCR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "XNCR Xencor Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.